Does Prevagen help in reducing memory loss?

You may have seen the ad for Prevagen during morning news shows or between innings of a Red Sox game: a video of a pulsating jellyfish, whose nervous system glows blue. The substance that provides the blue glow is protein called apoaequorin and it is very well studied. 

The commercial goes on to say that “a double blind placebo controlled study” suggests that Prevagen improves recall of older adults who have reported memory problems. If you freeze the screen it reads: “These statements have not been validated by the FDA.  And: Not intended to diagnose, treat, cure or prevent any disease.”  Then there is a graph that shows memory of impaired patients improving over 90 days. Sometimes the ads include a clip of a woman defeating her granddaughter at chess. 

As you might have suspected, there is a back-story.  Prevagen is a dietary supplement and thus escapes the scrutiny of the FDA: it needs only to be harmless, not effective. If it were a drug the FDA would have tested Prevagen for safety and effectiveness. Had it passed scrutiny (which I believe it would not), Prevagen would be sold with a package insert, with all manner of chemical information, pharmacodynamics (measurement of how long the drug lasts in the blood), and sites and mechanism of action. There would be data from clinical trials and references to the scientific literature. I read these things the way an investor tackles a financial report, but I have not found one for Prevagen.  The only insert is an order form to buy more. I bought a bottle of it to learn that there is no useful insert. 

The apoaequorin in Prevagen would have to survive the hydrochloric acid and protein destroying enzymes of the stomach; it would have to be absorbed in the small intestine; it would have to get into the blood stream, and it would have to pass the formidable defenses of the blood-brain barrier. It would have to get into affected nerve cells and improve their function. It would have to pick up a second small molecule to become the light emitting aequorin, rather than its precursor apoaequorin. There is no biological reason I can see to believe that it could improve memory or recall in impaired adults.

Quincy Biosciences, the maker of Prevagen, has funded a clinical trial, named the Madison Memory Study, which enrolled 218 adults between the ages of 40 and 91 and lasted for 90 days. The authors conclude that there is little overall difference between treated patients and patients given a placebo pill. However, if they sorted out patients who were minimally impaired to begin with according to a test of recall of words on a list, there seemed to be a slight improvement at the end of 90 days of taking Prevagen. This sort of post-hoc searching is not statistically valid. The reported data bear little relationship to the graph shown on TV, which is strange. The study was not peer-reviewed, nor was it listed in ClinicalTrials.gov, both serious breaches in the world of clinical trials. E-mail me for a PDF of the paper that reports this trial.

Advertising on major networks is expensive and Prevagen is advertised a lot.  A 30-pill supply lasts a month and costs $40, unless you buy the extra strength version, which costs $59. What worried family would hesitate, if there were even a small chance that Prevagen would help grandma?

How is it possible for a company to sell about $120 million worth of this stuff in a year? Dietary supplements face few constraints, except that they be harmless, which apoaequorin apparently is.  (It is made from recombinant DNA expressed in bacteria, not from jellyfish). Serious legal and political battles mounted by the dietary supplements industry have kept supplements away from the FDA. 

Prevagen is not completely safe from regulation. The Federal Trade Commission has accused the makers of fraudulent advertising and has acted against the company, joined by the New York attorney general’s office. The FTC and New York state lost the first round in court.  As I understand it, the judge ruled that Quincy Biosciences described their trial adequately and that was all that was required for a dietary supplement. The decision is mystifying to me on biological and statistical grounds, but we will see what the appeal brings. For a more sophisticated analysis of statistics in the law and as it pertains to this case, see the October 2017 blog by Rebecca Tushnet, Professor of Law at Harvard Law School. The blog is easily found at tushnet.blogspot.com.

Sadly, the failure of biomedical scientists to create treatments for dementia is partly to blame for the success of dietary supplements. This column will try to cover new information from the Alzheimer field and what is being done with the tripled NIH budget ($1.9 billion) for dementia studies of all kinds. 

Richard Kessin is Professor Emeritus of Pathology and Cell Biology at Columbia University. He lives in Norfolk and can be reached at Richard.Kessin@gmail.com

Latest News

To mow or not to mow?

To mow or not to mow?

A partially mowed meadow in early spring provides habitat for wildlife while helping to keep invasive plants in check.

Dee Salomon

Love it or hate it, there is no denying the several blankets of snow this winter were beautiful, especially as they visually muffled some of the damage they caused in the first place.There appears to be tree damage — some minor and some major — in many places, and now that we can move around, the pre-spring cleanup begins. Here, a heavy snow buildup on our sun porch roof crashed onto the shrubs below, snapping off branches and cleaving a boxwood in half, flattening it.

The other area that has been flattened by the snow is the meadow, now heading into its fourth year of post-lawn alterations. A short recap on its genesis: I simply stopped mowing a half-acre of lawn, planted some flowering plants, spread little bluestem seeds and, far less simply, obsessively pluck out invasive plants such as sheep sorrel and stilt grass. And while it’s not exactly enchanting, it is flourishing, so much so that I cannot bring myself to mow.

Keep ReadingShow less

Where the mat meets the market

Where the mat meets the market

Kathy Reisfeld

Elena Spellman

In a barn on Maple Avenue in Great Barrington, Kathy Reisfeld merges two unlikely worlds: wealth management and yoga, teaching clients and students alike how stability — financial and emotional — comes from practice.

Her life sits at an intersection many assume can’t exist: high finance and yoga. One world is often reduced to greed, the other to “woo-woo” stretching. Yet in conversation, she makes both feel grounded, less like opposites and more like two languages describing the same human need for stability.

Keep ReadingShow less
Capitol hosts first-ever staging of Civil War love story

Playwright Cinzi Lavin, left, poses with Kathleen Kelly, director of ‘A Goodnight Kiss.’

Jack Sheedy

Litchfield County playwright Cinzi Lavin’s “A Goodnight Kiss,” based on letters exchanged between a Civil War soldier and the woman who became his wife, premiered in 2025 to sold-out audiences in Goshen, where the couple once lived. Now the original cast, directed by Goshen resident Kathleen Kelly, will present the play beneath the gold dome of Connecticut’s Capitol in Hartford as part of the state’s America250 commemoration — marking what organizers believe may be the first such performance at the Capitol.

“I don’t believe any live performances of an actual play (at the Capitol) have happened,” said Elizabeth Conroy, administrative assistant at the Office of Legislative Management, who coordinates Capitol events.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Hunt Library launches VideoWall for filmmakers

Yonah Sadeh, Falls Village filmmaker and curator of David M. Hunt Library’s new VideoWall.

Robin Roraback

The David M. Hunt Library in Falls Village, known for promoting local artists with its ArtWall, is debuting a new feature showcasing filmmakers. The VideoWall will premiere Saturday, March 28, at 6 p.m. with a screening of two short films by Brooklyn-based documentary filmmaker and animator Imogen Pranger.

The VideoWall is the idea of Falls Village filmmaker Yonah Sadeh, who also serves as curator. “I would love the VideoWall to become a place that showcases the work of local filmmakers, and I hope that other creatives in the area will submit their work to be shown,” he said.

Keep ReadingShow less

A bowl full of stars

A bowl full of stars

A bowl full of stones.

Cheryl Heller

There’s a bowl in my studio where pieces of the planet reside. I bring them home from travels, picking them up not for their beauty or distinction but for their provenance. I choose the ones that speak to me — the ones next to pyramids, along hiking trails, on city sidewalks or volcanic slopes.

I like how stones feel in my hand: weighty, grounding. I don’t mind them making my pockets and suitcase heavier. The bowl is about the size of an average carry-on. It has been years since it was light enough for me to lift.

Keep ReadingShow less
One-woman show brings Mumbet’s fight for freedom to Scoville Library
One-woman show brings Mumbet’s fight for freedom to Scoville Library
One-woman show brings Mumbet’s fight for freedom to Scoville Library

On March 29, writer, producer and director Tammy Denease will embody the life and story of Elizabeth Freeman, widely known as Mumbet, in two performances at the Scoville Library in Salisbury. Presented by Scoville Library and the Salisbury Association Historical Society, the performance is part of Salisbury READS, a community-wide engagement with literature and civic dialogue.

Mumbet was the first enslaved woman in Massachusetts to sue successfully for her freedom in 1781. Her victory helped lay the legal groundwork for the abolition of slavery in the state just two years later. In bringing Mumbet’s story to life, Denease does more than reenact history.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.